Seagen claims Enhertu (trastuzumab deruxtecan ... include auristatin compounds coupled to an antibody via a linker molecule. The jury in the US District Court for the Eastern District of ...

Enhertu has emerged as an important new treatment option for HER2-positive breast cancer, but it was thought that, as a large molecule, it may not be able to penetrate effectively into the CNS.

Enhertu is approved for HR-positive, HER2-low or -ultralow metastatic breast cancer after endocrine therapy progression, based on DESTINY-Breast06 trial results. Enhertu showed a 36% reduction in ...

In the HER2-low population, treatment with trastuzumab deruxtecan reduced the risk of disease progression or death by 38% compared with chemotherapy. The Food and Drug Administration (FDA) has ...

Dr. Debu Tripathy discusses the FDA approval of Enhertu in unresectable or metastatic hormone receptor HR+, HER2-low or -ultralow breast cancer. On Jan. 27, the Food and Drug Administration (FDA) ...

AstraZeneca AZN and partner Daiichi Sankyo announced that the FDA has approved the supplemental biologics license application (sBLA) seeking approval for expanded use of Enhertu (trastuzumab ...

Enhertu has also earlier received the FDA ... by harnessing the targeting power of antibodies to deliver cytotoxic molecule drugs to tumors. Enhertu is presently approved for advanced or ...

The U.S. regulator has cleared Enhertu as the first HER2-directed treatment for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA ...

Enhertu (fam-trastuzumab deruxtecan-nxki ... "It's a lot more costly, generally, than what you would class as a small molecule drug that you can chemically synthesise." In early November, Melanie ...